Contineum Therapeutics, Inc. (CTNM) stock
CTNMNasdaqPharmaceutical PreparationsFiscal year ends December 31
$9.24−0.31 (-3.25%)
Close on Nov 18, 2026Market cap $347.62MP/E –Yield –
Contineum Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Contineum Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$66.38M. For fiscal 2025 it was -$68.06M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$68.06M | – |
| FY2024 | Dec 31, 2024 | -$50.89M | -416.6% |
| FY2023 | Dec 31, 2023 | $16.08M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$17.43M | – |
| Q1 FY2026 | Mar 31, 2026 | -$16.90M | – |
| Q4 FY2025 | Dec 31, 2025 | -$17.12M | – |
| Q3 FY2025 | Sep 30, 2025 | -$14.93M | – |
| Q2 FY2025 | Jun 30, 2025 | -$17.90M | – |
| Q1 FY2025 | Mar 31, 2025 | -$18.11M | – |
| Q4 FY2024 | Dec 31, 2024 | -$17.05M | – |
| Q3 FY2024 | Sep 30, 2024 | -$12.97M | – |
| Q2 FY2024 | Jun 30, 2024 | -$10.94M | -128.1% |
| Q1 FY2024 | Mar 31, 2024 | -$9.93M | – |
| Q4 FY2023 | Dec 31, 2023 | -$9.68M | – |
| Q3 FY2023 | Sep 30, 2023 | -$8.07M | – |
| Q2 FY2023 | Jun 30, 2023 | $38.94M | – |
| Q1 FY2023 | Mar 31, 2023 | -$5.12M | – |
See a number that looks wrong?